As most prostate tumors relapsed from androgen ablation therapy express AR and expression of mRNA and protein level of AR are frequently elevated [23-25], restoration of endogenous testosterone level by IAD treatment will suppress the proliferation of AR-rich relapsed prostate cancer cells based on observations in LNCaP 104-R1, 104-R2, CDXR, and in other relapsed prostate cancer cell models [15,18-22,31,32,55,57,58,61-65,74]. The gene discussed is AR; the disease is Familial prostate cancer.